
STATUTORY INSTRUMENTS

2019 No. 775

**The Human Medicines (Amendment
etc.) (EU Exit) Regulations 2019**

PART 15

Amendment of Part 14 (advertising)

Amendment of Schedule 30 (particulars for advertisements to persons qualified to prescribe or supply)

[^{F1}216. In Schedule 30—

- (a) in paragraphs 1, 2 and 6, for “marketing authorisation,” substitute “UK marketing authorisation, EU marketing authorisation”;
- (b) after paragraph 2 insert—

“**2A.** In relation to an advertisement in Great Britain (other than an advertisement falling within the exception in regulation 296) where the medicinal product concerned is authorised under a UKMA(GB), a statement that the product concerned is authorised under a UKMA(GB).”.]

Textual Amendments

- F1** Reg. 216 substituted (31.12.2020 immediately before IP completion day) by [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, [Sch. 2 para. 175](#)
-

Commencement Information

- I1** Reg. 216 in force at 31.12.2020 on IP completion day (in accordance with [2020 c. 1, Sch. 5 para. 1\(1\)](#)), see [reg. 1](#)

Changes to legislation:

There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019, Section 216.